Researchers in the laboratory of Yulia Nefedova, M.D., Ph.D., at The Wistar Institute and collaborators at Jubilant Therapeutics Inc. have uncovered a novel mechanism by which protein arginine deiminase 4 (PAD4) in neutrophils promotes cancer progression. The paper also found that inhibition of this function of PAD4 reduces primary tumor growth and metastasis and enhances checkpoint inhibitor treatments. Jubilant Therapeutics Inc. is developing a novel small molecule PAD4 inhibitor that directly targets this mechanism. The findings appear in Cancer Research.
You may also be interested in:
A cap-and-invest strategy to cut transportation-related carbon emissions could provide substantial health benefits to children in New York City, with greater benefits among Black and [...]
Playgrounds are fun and can provide a great opportunity for exercise and family togetherness. But did you know that youths age 17 and younger are [...]
According to a new modeling study, published in JAMA Pediatrics, the number of children estimated to have experienced the death of a parent or caregiver [...]